Patents in Class 424/260.100

Matches 1 - 50 out of 85

1 2 >

Match	Document	Document Title
1	7384639	Methods of treating or preventing an infectious disease using an immunogenic conjugate of a gram-negative bacterial autoinducer molecule The present invention relates to an immunogenic conjugate comprising a carrier molecule coupled to an autoinducer of a Gram negative bacteria The immunogenic conjugate, when combined with a...
2	7371394	Antigenic composition of a Pseudomonas aeruginosa protein A novel antigen from P. aeruginosa is provided. The use of the antigen in detecting/diagnosing P. aeruginosa as well as its use in eliciting an immune response are also provided.
3	7371393	Methods for reducing fecal shedding The present invention provides methods for reducing shedding in an animal. Generally, the method includes administcriirn to an animal a composition including siderophore receptor polypeptides and...
4	7341732	Methods for treating mastitis in a milk producing animal The present invention provides methods for treating mastitis in a milk producing animal. The methods include administering compositions including siderophore receptor polypeptides and porins from...
5	7338794	Amended recombinant cells for the production and delivery of gamma interferon as an antiviral agent, adjuvant and vaccine accelerant The present invention provides active cytokine and/or chemokine compositions, as well as inexpensive means for the production, amended-cell encasement of active cytokine and/or chemokine...
6	7314632	Pseudomonas exotoxin A-like chimeric immunogens This invention provides Pseudomonas exotoxin A-like chimeric immunogens that include a non-native epitope in the Ib domain of Pseudomonas exotoxin. Methods of eliciting an immune response using...
7	7268209	Peptides, derivates thereof, process for producing the same, novel strain producing the same, and antiviral agent comprising the same as active ingredient Peptides having, as constitutive amino acids, (1) 4 glutamine residues, 1 glutamic acid residue, 1 serine residue, 2 valine residues, 1 isoleucine residue and 5 leucine residues, and having a...
8	7183100	Aconitase A bacterial protein which converts 2-methyl citrate to 2-methyl isocitrate is a previously unknown target for antibacterial agents. The protein of this activity is associated with mucoid bacteria...
9	7166270	Methods of screening compounds useful for prevention of infection or pathogenicity Screening procedures are disclosed for identifying compounds useful for inhibiting infection or pathogenicity. Methods are also disclosed for identifying pathogenic virulence factors.
10	7160549	Methods for making compositions including gram negative microbial polypeptides The present invention provides methods for making compositions including siderophore receptor polypeptides and porins from gram negative microbes. The methods include providing a gram negative...
11	7052689	Method for producing therapeutically suitable glutaminase DNA encoding a therapeutically suitable glutaminase has been molecularly cloned. This allows one to obtain a polypeptide which is a therapeutically suitable glutaminase free of contaminating...
12	7029684	Antigenic composition of a Pseudomonas aeruginosa A novel antigen from P. aeruginosa is provided. The use of the antigen in detecting/diagnosing P. aeruginosa as well as its use in eliciting an immune response are also provided.
13	6951652	Vaccine for prevention of gram-negative bacterial infections and endotoxin related diseases A vaccine is disclosed which is useful for protecting a host from Gram negative infections and the effects of endotoxin, therefore preventing sepsis and septic shock. The vaccine is prepared by...
14	6942858	Compositions containing bacteriophages and methods of using bacteriophages to treat infections Purified, host-specific, non-toxic, wide host range and virulent bacteriophage preparations that are effective in killing bacterial organisms in vivo are disclosed. Also disclosed are compositions...
15	6936447	Autoinducer molecule Autoinducer molecules, e.g., N-(3-oxododecanoyl)homoserine lactone, for Pseudomonas aeruginosa are described. The molecules regulate gene expression in the bacterium. Therapeutic compositions and...
16	6936263	Th1 inducing natural adjuvant for heterologous antigens The present invention relates to the use of the major OprI lipoprotein of Pseudomonas aeruginosa to elicit a Type-1 immune response towards a heterologous antigen. The invention relates...
17	6905692	Topical compositions containing probiotic bacillus bacteria, spores, and extracellular products and uses thereof The present invention discloses compositions derived from an isolated Bacillus species, spores, or an extracellular product of Bacillus coagulans comprising a supernatant or filtrate of a...
18	6872398	Conjugate vaccine against gram-negative bacterial infections The present invention relates to a broadly reactive vaccine against Gram-negative bacteria which is composed of a biological glycan-pilus conjugate. The conjugate core is a common pilus type to...
19	6793925	Pseudomycin natural products The invention relates to pseudomycin natural products including pseudomycins A′ and B′, methods for making such pseudomycins, and methods employing antifungal activity of these pseudomycins....
20	6767545	Pseudomonas treatment composition and method A composition and method for treating or preventing infection by Pseudomonas aeruginosa is disclosed. The composition includes a P. aeruginosa pilin peptide modified to prevent oligomerization...
21	6696064	Methods of protecting vasculature from damage by diphtheria toxin-and pseudomonas toxin-based immunotoxins during therapy Vascular damage has proven to be dose limiting in administering immunotoxins into the brain to treat brain tumors. Vascular toxicity of immunotoxins which rely in part on exposure to lowered pH in...
22	6645506	Topical compositions containing extracellular products of Pseudomonas lindbergii and Emu oil The present invention discloses compositions derived from an isolated Bacillus species, spores, or an extracellular product of Bacillus coagulans comprising a supernatant or filtrate of a culture...
23	6548287	Non-pyrogenic bacterial strains and use of the same The present invention provides gram-negative bacterial strains that produce substantially pure non-pyrogenic lipopolysaccharide or lipid A. The present invention also relates to a use of said...
24	6541007	Vaccine for Pseudomonas aeruginosa A C-terminal pilin peptide vaccine for immunizing or treating a patient for infection by a Pseudomonas aeruginosa (PA) infection is disclosed. The peptide comprises the peptide identified as SEQ...
25	6531133	Pseudomonas exotoxin-myelin basic protein chimeric proteins A chimeric protein comprising a Pseudomonas aeruginosa exotoxin (PE) moiety linked to a myelin basic protein (MBP) moiety is disclosed. The MBP moiety is selected from the group comprising: (a)...
26	6426075	Protease-activatable pseudomonas exotoxin A-like proproteins This invention provides protease-activatable Pseudomonas exotoxin A-like (“PE-like”) proproteins. The proproteins comprise (1) a cell recognition domain of between 10 and 1500 amino acids that...
27	6423513	Polynucleotides encoding protease-activatable pseudomonas exotoxin a-like proproteins This invention provides protease-activatable Pseudomonas exotoxin A-like (“PE-like”) proproteins. The proproteins comprise (1) a cell recognition domain of between 10 and 1500 amino acids that...
28	6395282	Immunogenic conjugates of Gram-negative bacterial autoinducer molecules The present invention relates to an immunogenic conjugate comprising a carrier molecule coupled to an autoinducer of a Gram negative bacteria. The immunogenic conjugate, when combined with a...
29	6300102	Immunogenic hybrid protein OprF-Oprl derived from Pseudomonas aeruginosa membrane proteins The present invention relates to a hybrid protein comprising the Pseudomonas aeruginosa outer membrane protein I (OprI) which is fused with its amino terminal end to the carboxy-terminal end of a...
30	6270777	Conserved metalloprotease epitopes The present invention provides immunogenic compositions comprising peptides derived from the amino acid sequence of P. aeruginosa for protecting susceptible hosts against diseases caused by...
31	6221386	Use of virulence factors of pathogens to improve liposomal delivery of therapeutic agents Liposome encapsulated antibiotic therapy has limited application against infectious organisms, which can sequester in non-phagocytic cells. Virulence factors of these infectious organisms, for...
32	6183756	Methods for prevention and/or treatment of thrombocytopenia The present invention is directed to a method of treating subjects exhibiting thrombocytopenia or at risk of developing thrombocytopenia. The method includes the step of administering to the...
33	6121296	Transition-state inhibitors for nucleoside hydrolase and transferase reactions This invention is directed to transition-state analog compounds and to the use of said compounds as inhibitors of nucleoside hydrolase and transferase enzyme activity of parasites. This invention...
34	6083928	Skin healing method A method for facilitating the healing of skin comprising applying topically to skin a composition containing an amount of a lipopolysaccharide extracted from gram negative bacteria effective to...
35	6045805	Oligosaccharide derived from an antigenic polysaccharide obtained from a pathogenic agent An oligosaccharide derived from an antigen polysaccharide obtained from a pathogenic agent, a method for its preparation, and its use particularly as a vaccinal agent. The oligosaccharide is...
36	5997881	Method of making non-pyrogenic lipopolysaccharide or A The present invention provides gram-negative bacterial strains that produce substantially pure non-pyrogenic lipopolysaccharide or lipid A. The present invention also relates to a use of said...
37	5955090	Immunogenic hybrid protein OprF-OprI derived from Pseudomonas aeruginosa membrane proteins The present invention relates to a hybrid protein comprising the Pseudomonas aeruginosa outer membrane protein I (OprI) which is fused with its amino terminal end to the carboxy-terminal end of a...
38	5951987	Polysaccharide vaccine to enhance immunity against brucellosis A vaccine comprising purified outer-polysaccharide (OPS) is effective for protection against brucellosis. The vaccine is derived from Brucella or a variety of cross reactive bacteria. The vaccine...
39	5906826	Method of inducing an immune response in a young animal The invention provides a method of priming an immune response in the presence of maternal antibody in a young animal by administering to a 1-90 day old animal, a biocompatible and non-toxic solid...
40	5861163	Process for preparing a vaccine against pseudomonas aeruginosa using attenuated strains The present invention relates to a vaccine prepared from an attenuated Pseudomonas aeruginosa strains which are obtained by isolating Pseudomonas aeruginosa in a pure state according to the...
41	5853738	Methods for treatment of human immunodeficiency virus infection with pseudomonas phosphoaminolipid extract The present invention is directed to a method of treating individuals infected with HIV or at risk of being infected with HIV. The method comprises the step of administering to an individual...
42	5851534	Methods for prevention and/or treatment of neutropenia The present invention is directed to a method of treating individuals exhibiting neutropenia or at risk of neutropenia. The method comprises the step of administering to an individual exhibiting...
43	5827718	Lipase, microorganisms producing the lipase, method of producing the lipase and use of the lipase Bacteria belonging to the genus Pseudomonas, alkaline lipase produced by the bacteria and having the following properties, a method of producing the lipase, and detergent compositions containing...
44	5705163	Target-specific, cytotoxic, recombinant pseudomonas exotoxin A target-specific, cytotoxic, recombinant Pseudomonas exotoxin is described. Such toxins are made by inserting specific recognition molecules at specific cloning sites in at least domain III near...
45	5705156	Psuedomonas exotoxins of low animal toxicity and high cytocidal activity Improved Pseudomonas exotoxins of low animal toxicity and high cytocidal activity are described. Substitution of positively charged amino acid residues with an amino acid residue without a positive...
46	5628996	Method for inhibiting the viability of Pseudomonas aeruginosa with cross-reactive and cross-protective monoclonal antibodies Cell lines have been produced that secrete human monclonal antibodies capable of binding to the lipopolysaccharide molecules of selected Pseudomonas aeruginosa IATS serotypes. Pharmaceutical...
47	5623057	Pneumococcal polysaccharide conjugate vaccine A novel conjugate vaccine comprising partially hydrolyzed, highly purified, capsular polysaccharide (Ps) from Streptococcus pneumoniae bacteria (pneumococci, Pn) linked to an immunogenic carrier...
48	5612036	Synthetic Pseudomonas aeruginosa pilin peptide vaccine Treatment and diagnosis of P. aeruginosa infection or colonization is achieved in accordance with this invention by the discovery of a polypeptide which is smaller than the naturally occurring P....
49	5538727	Anti-cholesterolemic vaccine Anti-cholesterolemic eggs are disclosed, said eggs being obtained from animals hyperimmunized against at least one anti-cholesterolemic antigen. A vaccine producing said anti-cholesterolemic egg is...
50	5512658	Pseudomonas exotoxins (PE) and conjugates thereof having lower animal toxicity with high cytocidal activity through substitution of positively charged amino acids Improved Pseudomonas exotoxins of low animal toxicity and high cytocidal activity are described. Substitution of positively charged amino acid residues with an amino acid residue without a positive...

Matches 1 - 50 out of 85

1 2 >